BELLUS Health Inc. (BELLUS Health) is engaged in developing drugs for rare diseases, starting with conditions that affect the kidneys. The Company’s lead program is KIACTA, a drug candidate in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is involved in a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body, including the kidneys, heart, liver and peripheral nerves. It is developing Shigamab, an antibody treatment for hemolytic uremic syndrome caused by Shiga toxin-producing E. coli (sHUS). Shigamab is a monoclonal antibody therapy being developed for the treatment of sHUS. It principally affects the kidneys and often leads to acute dialysis, and in certain cases chronic kidney disease and death, primarily in children.